Cargando…
443. Pre-vaccination Antibody Titers Against Seasonal Coronaviruses And Antibody Responses to the Pfizer-BioNTech BNT162b2 COVID-19 mRNA Vaccine in Healthcare Workers
BACKGROUND: The Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study is following over 200 healthcare workers who have received the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. A major aim of the study is to determine whether baseline antibody titers against the seasonal human coronav...
Autores principales: | Laing, Eric, Coggins, Si’Ana, Schully, Kevin, Samuels, Emily, Goguet, Emilie, Moser, Matthew, Jackson-Thompson, Belinda, Pollett, Simon, Tribble, David, Davies, Julian, Illinik, Luca, Hollis-Perry, Monique, Maiolatesi, Santina, Duplessis, Christopher, Ramsey, Kathleen, Reyes, Anatalio, Alcorta, Yolanda, Wong, Mimi, Ortega, Orlando, Wang, Gregory, Parmelee, Edward, Lindrose, Alyssa, Burgess, Timothy, Broder, Christopher C, Mitre, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644617/ http://dx.doi.org/10.1093/ofid/ofab466.642 |
Ejemplares similares
-
Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers
por: Coggins, Si’Ana A, et al.
Publicado: (2021) -
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers
por: Laing, Eric D., et al.
Publicado: (2022) -
Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
por: Graydon, Elizabeth K., et al.
Publicado: (2023) -
2349. Natural Killer Cells and BNT162b2 mRNA Vaccine Reactogenicity and Durability
por: Graydon, Elizabeth K, et al.
Publicado: (2023) -
Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers
por: Jackson-Thompson, Belinda M., et al.
Publicado: (2021)